ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: FK949E

First Posted Date: 2013-08-16

Last Posted Date: 2017-02-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 32

Registration Number: NCT01924520

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: FK949E

First Posted Date: 2013-08-08

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 16

Registration Number: NCT01919008

Drug Use-Results Survey of Betanis Tablets in Japan

Completed

Conditions: Overactive Bladder

Interventions: Drug: Betanis

First Posted Date: 2013-08-08

Last Posted Date: 2015-10-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 10711

Registration Number: NCT01919047

Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of Quetiapine

Interventions: Drug: FK949E
Drug: fluvoxamine

First Posted Date: 2013-07-25

Last Posted Date: 2017-02-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01908296

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Completed

Conditions: Chronic Renal Failure

Interventions: Drug: bixalomer

First Posted Date: 2013-07-19

Last Posted Date: 2024-10-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 123

Registration Number: NCT01903213

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Phase 1

Completed

Conditions: Major Depressive Disorder Patients

Interventions: Drug: FK949E

First Posted Date: 2013-07-19

Last Posted Date: 2017-02-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 16

Registration Number: NCT01903200

A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant

Phase 2

Completed

Conditions: Allogeneic Hematopoietic Cell Transplant

Interventions: Biological: ASP0113

First Posted Date: 2013-07-19

Last Posted Date: 2024-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 9

Registration Number: NCT01903928

Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients

Completed

Conditions: Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis

Interventions: Drug: Kiklin capsules

First Posted Date: 2013-07-17

Last Posted Date: 2017-01-27

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1078

Registration Number: NCT01901107

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Completed

Conditions: Overactive Bladder

Interventions: Drug: Betanis

First Posted Date: 2013-07-17

Last Posted Date: 2016-11-01

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1263

Registration Number: NCT01901120

Specified Drug Use-results Survey of Betanis Tablets

Completed

Conditions: Overactive Bladder

Interventions: Drug: mirabegron

First Posted Date: 2013-07-12

Last Posted Date: 2018-02-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 300

Registration Number: NCT01898624

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy